Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
复制标题
与未经修饰的干扰素 α-2a [Roferon-A] 相比，聚乙二醇干扰素 α-2a (40kD) [Pegasys] 可改善慢性丙型肝炎患者的 HR-QOL 结果。
作者：
J. Rasenack;S. Zeuzem;S. Feinman;E. Heathcote;M. Manns;E. Yoshida;M. Swain;E. Gane;M. Diago;D. Revicki;A. Lin;N. Wintfeld;Jesse Green
背景
BACKGROUND
Use of unmodified interferon alpha-2a in chronic hepatitis C is associated with impaired health-related quality of life during therapy. Treatment with peginterferon alpha-2a (40kD) provides an improved sustained response over unmodified interferon alpha-2a.
OBJECTIVES
To compare health-related quality of life during treatment for patients receiving peginterferon alpha-2a (40kD) [Pegasys] versus unmodified interferon alpha-2a [Roferon].
DESIGN
A randomised, international, multicentre, open-label, parallel group study.
SETTING
36 centres worldwide.
PATIENTS
Interferon-naïve patients (n = 531) with chronic hepatitis C.
INTERVENTIONS
Peginterferon alpha-2a (40kD) 180 mirog once a week (n = 267) for 48 weeks or unmodified interferon alpha-2a 6 million IU three times a week for 12 weeks followed by 36 weeks of 3 million IU three times a week (n = 264).
MEASUREMENTS
Fatigue Severity Scale and 36-item Short-Form Health Survey (SF-36).
RESULTS
At weeks 2 and 12, differences favouring peginterferon alpha-2a (40kD) were seen on seven of eight domains and both summary scores of the SF-36 (p < 0.05 to p < 0.01). At weeks 2, 12 and 24, patients receiving peginterferon alpha-2a (40kD) had less disabling fatigue (p < 0.01) than those receiving unmodified interferon alpha-2a.
CONCLUSION
Treatment with peginterferon alpha-2a (40kD) is associated with less disabling fatigue and less impairment in patient functioning and well-being during treatment than unmodified interferon alpha-2a. In addition to safety and efficacy, the impact on health-related quality of life may be an important consideration for physicians when selecting an optimal treatment regimen.